Abilify Generics Infringe Otsuka Patent, Fed. Circ. Told
Otsuka Pharmaceutical Co. Ltd. urged a Federal Circuit panel Monday to revive its suit against pharmaceutical companies seeking to market generic versions of the antidepressant Abilify, arguing a New Jersey federal...To view the full article, register now.
Already a subscriber? Click here to view full article